Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 11/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19756269 | 1.00 | HDAC1 (0.35) | HDAC1HDAC2HDAC6GLSALDH1A1 | |
| SCHEMBL19756268 | 1.00 | HDAC1 (0.35) | HDAC1HDAC2HDAC6GLSALDH1A1 | |
| SCHEMBL19756278 | 0.98 | ALDH1A1 (0.35) | HDAC1HDAC2HDAC6GLSALDH1A1 | |
| SCHEMBL19756267 | 0.92 | ALDH1A1 (0.37) | HDAC1HDAC2HDAC6GLSALDH1A1 | |
| SCHEMBL23521092 | 0.85 | HDAC1 (0.33) | HDAC1HDAC2HDAC6ALDH1A1KDM4A | |
| SCHEMBL8567763 | 0.83 | ALDH1A1 (0.52) | HDAC1HDAC2HDAC6ALDH1A1KDM4A | |
| SCHEMBL26489607 | 0.83 | ALDH1A1 (0.37) | GLSALDH1A1 | |
| SCHEMBL20644805 | 0.83 | ALDH1A1 (0.35) | HDAC1HDAC2HDAC6ALDH1A1KDM4A | |
| SCHEMBL23521083 | 0.83 | ALDH1A1 (0.35) | HDAC1HDAC2HDAC6ALDH1A1KDM4A | |
| SCHEMBL13644766 | 0.83 | ALDH1A1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2023-01-31 | — | — | US | disclosed |
| US-20220211817-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2022-07-07 | — | — | US | disclosed |
| US-11311604-B2 | Controlled-release CNP agonists with low NPR-C binding | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-04-26 | — | — | US | disclosed |
| US-20220118053-A1 | Dry Pharmaceutical Formulations of CNP Conjugates | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-04-21 | — | — | US | disclosed |
| US-11224661-B2 | Controlled-release CNP agonists with increased NEP stability | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20210077584-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2021-03-18 | — | — | US | disclosed |
| US-20210069339-A1 | CNP PRODRUGS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2021-03-11 | — | — | US | disclosed |
| US-10835578-B2 | CNP prodrugs with large carrier moieties | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2020-11-17 | — | — | US | disclosed |
| US-20200276270-A1 | Combination Therapy with Controlled-Release CNP Agonists | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2020-09-03 | — | — | US | disclosed |
| US-20190328840-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-10-31 | — | — | US | disclosed |
| US-20190255183-A1 | CNP PRODRUGS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| US-20190022237-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-24 | — | — | US | disclosed |
| US-20190015481-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-17 | — | — | US | disclosed |
| US-20190000926-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-03 | — | — | US | disclosed |
| US-20170368189-A1 | CNP PRODRUGS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069339-A1 | CNP PRODRUGS | NPPA, NPR1, NPR3 | HDAC1 3685/4885HDAC2 4155/4885HDAC6 4110/4885 |
| US-20190255183-A1 | CNP PRODRUGS | NPPA, NPR1, NPR3 | HDAC1 3685/4885HDAC2 4155/4885HDAC6 4110/4885 |
| US-20190328840-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY | NPR1, NPR3, CNP | HDAC1 4154/4885HDAC2 3788/4885HDAC6 4012/4885 |
| US-20200276270-A1 | Combination Therapy with Controlled-Release CNP Agonists | CNP, NPR1, NGF | HDAC1 2943/4885HDAC2 3460/4885HDAC6 2396/4885 |
| US-20190022237-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY | CNP, NPR1, NPPA | HDAC1 3344/4885HDAC2 3099/4885HDAC6 2790/4885 |
| US-20190000926-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | NPR1, NPR3, NPSR1 | HDAC1 3587/4885HDAC2 3326/4885HDAC6 3214/4885 |
| US-20210077584-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | CNP, LNPEP, CSGALNACT1 | HDAC1 42/4885HDAC2 153/4885HDAC6 379/4885 |
| US-20220211817-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | NPR1, NPR3, NPSR1 | HDAC1 3587/4885HDAC2 3326/4885HDAC6 3214/4885 |
| US-11311604-B2 | Controlled-release CNP agonists with low NPR-C binding | NPR1, NPR3, NPSR1 | HDAC1 3587/4885HDAC2 3326/4885HDAC6 3214/4885 |
| US-11224661-B2 | Controlled-release CNP agonists with increased NEP stability | CNP, NPR1, NPPA | HDAC1 3344/4885HDAC2 3099/4885HDAC6 2790/4885 |
| US-20220118053-A1 | Dry Pharmaceutical Formulations of CNP Conjugates | CNP, PTMS, NPPA | HDAC1 2825/4885HDAC2 1366/4885HDAC6 338/4885 |
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | CNP, NPR1, NGF | HDAC1 2943/4885HDAC2 3460/4885HDAC6 2396/4885 |
| US-10835578-B2 | CNP prodrugs with large carrier moieties | CNP, LNPEP, CSGALNACT1 | HDAC1 42/4885HDAC2 153/4885HDAC6 379/4885 |
| US-20190015481-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | CNP, LNPEP, CSGALNACT1 | HDAC1 42/4885HDAC2 153/4885HDAC6 379/4885 |
| US-20170368189-A1 | CNP PRODRUGS | NPPA, NPR1, NPR3 | HDAC1 3685/4885HDAC2 4155/4885HDAC6 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.